Market Overview:
The global chronic obstructive pulmonary disorder (COPD) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The COPD market is segmented on the basis of type, application and region. On the basis of type, short-acting bronchodilators are expected to dominate the COPD market in terms of revenue share during the forecast period. This can be attributed to their high usage rates for relief from acute symptoms associated with COPD. By application, hospitals are expected to account for a majority share in terms of revenue generated by the COPD market during 2018-2030.
Product Definition:
Chronic obstructive pulmonary disorder (COPD) is a long-term lung disease that makes it difficult to breathe. COPD is the fourth leading cause of death in the United States. Symptoms include coughing, wheezing, shortness of breath, and chest tightness.
Short-Acting Bronchodilators:
Short-acting bronchodilators are a type of bronchodilator medication. It works by opening up the airways and reducing the amount of narrowing that is happening in the airways, which enables oxygen to reach all parts of the lung. Bronchodilators are used for treating chronic obstructive pulmonary disorder (COPD) and acute severe COPD.
Corticosteroids:
Corticosteroids are the group of drugs, which acts as anti-inflammatory agents. Corticosteroid medication is used for the treatment of asthma and other chronic respiratory diseases. The most commonly used corticosteroids are beclometasone (Beconase), deflazacort (Emflaza), fluticasone (Nebcin), mometasone (Asmanexin) and prednisolone (Disalc).
Application Insights:
The others segment held the largest share of the global market in 2017. This is due to an increase in the number of patients suffering from COPD and a rise in R&D activities for new drug development for COPD. The hospital segment is expected to be fastest growing application over the forecast period owing to increasing prevalence of chronic bronchitis and emphysema, which requires treatment with long-acting bronchodilators.
Chronic respiratory diseases are one of the leading causes of death globally; however, there has been an increase in life expectancy since 1990s as a result of advancements made regarding healthcare facilities and treatments worldwide. According to WHO, around 1 billion people suffer from some form or another of Chronic Obstructive Pulmonary Disease (COPD).
Regional Analysis:
North America dominated the global chronic obstructive pulmonary disorder market in 2017. The high prevalence of COPD and other respiratory diseases, rising healthcare expenditure, and increasing awareness about available treatment options are some of the major factors contributing to its growth. Moreover, an increase in smoking rates has further increased the demand for COPD treatments in this region. According to CDC’s National Center for Health Statistics (NCHS), approximately 15 million adults were diagnosed with COPD in U.S., which is nearly double that reported by NCHS back in 2001.
Asia Pacific is expected to register a lucrative growth rate over the forecast period owing to improving economic conditions and growing population especially among emerging countries such as India & China & Indonesia etc.
Growth Factors:
- Increasing prevalence of chronic obstructive pulmonary disorder (COPD) due to changing lifestyle and environmental factors.
- Growing awareness about COPD and its symptoms among people, which is likely to increase the diagnosis rate of COPD in the coming years.
- Rising demand for novel therapeutics for the treatment of COPD, especially from emerging markets.
- increasing number of smokers across the globe, which is a major risk factor for developing COPD 5
Scope Of The Report
Report Attributes
Report Details
Report Title
Chronic Obstructive Pulmonary Disorder Market Research Report
By Type
Short-Acting Bronchodilators, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators, Phosphodiesterase-4 Inhibitors, Others
By Application
Hospitals, Clinics, Others
By Companies
GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma, Roche, Ache, Almirall, Aquinox Pharmaceuticals, Asmacure, Astellas Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
132
Number of Tables & Figures
93
Customization Available
Yes, the report can be customized as per your need.
Global Chronic Obstructive Pulmonary Disorder Market Report Segments:
The global Chronic Obstructive Pulmonary Disorder market is segmented on the basis of:
Types
Short-Acting Bronchodilators, Corticosteroids, Methylxanthines, Long-Acting Bronchodilators, Phosphodiesterase-4 Inhibitors, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GSK
- Pfizer
- Merck
- Novartis
- AstraZeneca
- Boehringer Ingelheim
- Teva Pharmaceuticals
- Ario Pharma
- Roche
- Ache
- Almirall
- Aquinox Pharmaceuticals
- Asmacure
- Astellas Pharma
Highlights of The Chronic Obstructive Pulmonary Disorder Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Short-Acting Bronchodilators
- Corticosteroids
- Methylxanthines
- Long-Acting Bronchodilators
- Phosphodiesterase-4 Inhibitors
- Others
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Chronic Obstructive Pulmonary Disorder Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Chronic obstructive pulmonary disorder (COPD) is a serious lung disease that makes it difficult for the lungs to breathe. COPD can be caused by many things, including smoking, exposure to air pollution, and certain diseases. COPD often leads to other health problems, such as heart disease and diabetes.
Some of the key players operating in the chronic obstructive pulmonary disorder market are GSK, Pfizer, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Ario Pharma, Roche, Ache, Almirall, Aquinox Pharmaceuticals, Asmacure, Astellas Pharma.
The chronic obstructive pulmonary disorder market is expected to register a CAGR of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Chronic Obstructive Pulmonary Disorder Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Chronic Obstructive Pulmonary Disorder Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Chronic Obstructive Pulmonary Disorder Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Chronic Obstructive Pulmonary Disorder Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Chronic Obstructive Pulmonary Disorder Market Size & Forecast, 2020-2028 4.5.1 Chronic Obstructive Pulmonary Disorder Market Size and Y-o-Y Growth 4.5.2 Chronic Obstructive Pulmonary Disorder Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Short-Acting Bronchodilators
5.2.2 Corticosteroids
5.2.3 Methylxanthines
5.2.4 Long-Acting Bronchodilators
5.2.5 Phosphodiesterase-4 Inhibitors
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Chronic Obstructive Pulmonary Disorder Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Chronic Obstructive Pulmonary Disorder Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Short-Acting Bronchodilators
9.6.2 Corticosteroids
9.6.3 Methylxanthines
9.6.4 Long-Acting Bronchodilators
9.6.5 Phosphodiesterase-4 Inhibitors
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Short-Acting Bronchodilators
10.6.2 Corticosteroids
10.6.3 Methylxanthines
10.6.4 Long-Acting Bronchodilators
10.6.5 Phosphodiesterase-4 Inhibitors
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Short-Acting Bronchodilators
11.6.2 Corticosteroids
11.6.3 Methylxanthines
11.6.4 Long-Acting Bronchodilators
11.6.5 Phosphodiesterase-4 Inhibitors
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Short-Acting Bronchodilators
12.6.2 Corticosteroids
12.6.3 Methylxanthines
12.6.4 Long-Acting Bronchodilators
12.6.5 Phosphodiesterase-4 Inhibitors
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Short-Acting Bronchodilators
13.6.2 Corticosteroids
13.6.3 Methylxanthines
13.6.4 Long-Acting Bronchodilators
13.6.5 Phosphodiesterase-4 Inhibitors
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Chronic Obstructive Pulmonary Disorder Market: Competitive Dashboard
14.2 Global Chronic Obstructive Pulmonary Disorder Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 GSK
14.3.2 Pfizer
14.3.3 Merck
14.3.4 Novartis
14.3.5 AstraZeneca
14.3.6 Boehringer Ingelheim
14.3.7 Teva Pharmaceuticals
14.3.8 Ario Pharma
14.3.9 Roche
14.3.10 Ache
14.3.11 Almirall
14.3.12 Aquinox Pharmaceuticals
14.3.13 Asmacure
14.3.14 Astellas Pharma